Vistagen fails in late-stage trial for social anxiety disorder therapy

vistagen-fails-in-late-stage-trial-for-social-anxiety-disorder-therapy
Paper cutout of a human head with tangled mess of black lines.

mohd izzuan/iStock via Getty Images

Vistagen (VTGN) on Wednesday announced that a Phase 3 trial for fasedienol, an experimental therapy for social anxiety disorder, did not achieve its primary endpoint. Shares of the California-based biotech traded lower in the premarket immediately after the announcement.

Citing